Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a chronic or chronically relapsing inflammatory skin condition that primarily affects children. Topical corticosteroids have been the mainstay of treatment since the late 1950s. While providing excellent short-term efficacy, topical corticosteroid usage is limited by potential adverse effects, including impairment of the function and viability of Langerhans cells/dendritic cells. The recently introduced topical calcineurin inhibitors pimecrolimus cream 1% (Elidel®) and tacrolimus ointment 0.03 and 0.1% (Protopic®) exhibit a more selective mechanism of action and do not affect Langerhans cells/dendritic cells. For the immune system of young children ‘learning’ to mount a balanced Th1/Th2 response, this selective effect has particular benefits. In clinical experience, topical calcineurin inhibitors have been shown to be a safe and effective alternative to topical corticosteroids in almost 7 million patients (>5 million on pimecrolimus; >1.7 million on tacrolimus). Topical pimecrolimus is primarily used in children with mild and moderate AD, whereas tacrolimus is used preferentially in more severe cases. None of the topical calcineurin inhibitors have been associated with systemic immunosuppression-related malignancies known to occur following long-term sustained systemic immunosuppression with oral immunosuppressants (e.g., tacrolimus, cyclosporine A, and corticosteroids) in transplant patients. Preclinical and clinical data suggest a greater skin selectivity and larger safety margin for topical pimecrolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Atopic dermatitis and the atopic march
Spergel, J. M., & Paller, A. S. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.033 · Cited by 1,229
Self-citationGustafsson, D., Sjöberg, O., & Foucard, T. (2000) · Allergy · doi:10.1034/j.1398-9995.2000.00391.x · Cited by 457
TURPEINEN, M., SALO, O. P., & LEISTI, S. (1986) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1986.tb06242.x · Cited by 104 · cited 1×
“F03 Systemic Absorption of Topical Treatments for ADIn a pharmacokinetic study in children treated with hydrocortisone cream 1p (no occlusion), an increase of cortisol plasma levels over baseline of 77–967 ng/ml (212–2,669 nmol/l) has been reported, with HPA axis suppression observed in 38p of these patients [”
Cited by
Akdis, C. A., Akdis, M., Bieber, T., Bindslev‐Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01153.x · Cited by 733
Self-citationAkdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.03.045 · Cited by 460
Self-citationEvidence‐based (S3) Guideline on (anogenital) Lichen sclerosus
Kirtschig, G., Becker, K., Günthert, A., Jasaitiene, D., Cooper, S., Chi, C. ‐., Kreuter, A., Rall, K. K., Aberer, W., Riechardt, S., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13136 · Cited by 350
Management of Atopic Dermatitis in the Pediatric Population
Krakowski, A. C., Eichenfield, L. F., & Dohil, M. A. (2008) · Pediatrics · doi:10.1542/peds.2007-2232 · Cited by 205
A Comprehensive Review of the Treatment of Atopic Eczema
Lee, J. H., Son, S. W., & Cho, S. H. (2016) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2016.8.3.181 · Cited by 112
“Topical immunomodulators, tacrolimus and pimecrolimus, are nonsteroidal, topical calcineurin inhibitors.(43) They bind to FK-binding protein and inhibit the production of cytokines from activated T cells and inflammatory cells.”
Metadata
- Authors
- Hultsch, T., Kapp, A., & Spergel, J.
- Venue
- Dermatology
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 211
- Issue
- 2
- Pages
- 174-187
- ISSN
- 1018-8665 (ISSN-L)
- 1421-9832
- OpenAlex
- W2028507366
- Cited by
- 141
- References
- 4
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis. https://app.cochat.ai/papers/10.1159/000086739
- The paper
- Hultsch, T., Kapp, A., & Spergel, J. (2005). Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis. Dermatology. https://doi.org/10.1159/000086739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.